about
Response to radiation in renal medullary carcinomaPreclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of neuroblastomaPreclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of pediatric solid tumorsOncolytic virotherapy for pediatric malignancies: future prospectsHerpes simplex virus oncolytic therapy for pediatric malignanciesExpression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro.Targeting pediatric cancer stem cells with oncolytic virotherapyChanging trends of research and treatment in infant neuroblastoma.γ₁34.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxia.Hypoxia Moderates γ(1)34.5-Deleted Herpes Simplex Virus Oncolytic Activity in Human Glioma Xenoline Primary Cultures.Pediatric cancer gone viral. Part II: potential clinical application of oncolytic herpes simplex virus-1 in children.Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children.Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses.Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapyEffect of Repeat Dosing of Engineered Oncolytic Herpes Simplex Virus on Preclinical Models of RhabdomyosarcomaOncolytic viral therapy: targeting cancer stem cellsOncolytic Virotherapy for the Treatment of Malignant Glioma.Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy.The role of Src family kinases in growth and migration of glioma stem cells.Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature.Protocol for Reducing Time to Antibiotics in Pediatric Patients Presenting to an Emergency Department With Fever and Neutropenia: Efficacy and Barriers.Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors.Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111Attack of the cancer-killing viruses: clinical application of oncolytic virotherapy in children.Combination strategies enhance oncolytic virotherapy.Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002.Cerebral Ischemia Increases Small Ubiquitin-Like Modifier Conjugation within Human Penumbral Tissue: Radiological-Pathological Correlation.Treatment of children with glioblastoma with conformal radiation, temozolomide, and bevacizumab as adjuncts to surgical resection.Publication outcomes of abstracts from the American Society of Hematology Annual Meeting.Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomas.FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts.Drugging SUMOylation for neuroprotection and oncotherapy.Long-term complete response after treatment with cytarabine, vincristine, and prednisone in an infant with refractory multisystem Langerhans cell histiocytosis.Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 ExpressionQuality Initiative to Improve time to Antibiotics for Febrile Pediatric Patients with Potential NeutropeniaSUMOylation promotes survival and integration of neural stem cell grafts in ischemic strokeTreatment-induced remission of medulloblastoma using a chemotherapeutic regimen devoid of vincristine in a child with Charcot-Marie-Tooth diseaseSUMOylation in Glioblastoma: A Novel Therapeutic TargetMyelofibrosis in a patient with familial hemophagocytic lymphohistiocytosisSubsequent Neoplasms After a Primary Tumor in Individuals With Neurofibromatosis Type 1
P50
Q24631765-DF65AF46-EC10-4C87-AC1E-58C905D6BDDCQ27303714-C9E89BEA-9D1B-48BB-9A73-573F9381BDFCQ27329466-779FCF9F-DCF0-4C50-8222-38A4D78AFCE8Q28069358-F496E2B7-6CD4-450C-A19F-12F2DAF3758EQ33713824-C3884C5E-9FA0-4760-A230-6B97C0A5E184Q33824979-C0A5E046-7696-47DD-BB1E-0717C3794E7AQ34262327-E3C88859-292D-4D45-9472-D221C157113CQ34702987-43FC0499-59B1-4CF1-994C-271B38AD71C6Q35251719-1A37F51D-5D9B-476D-8F00-9B9609B2F9B6Q36061803-0D9E810E-7D8F-407E-9AD4-A2D08E4AF85AQ36109700-69216D30-044C-4D2C-BF03-627906CB6330Q36109704-CD2F28C0-5CE4-447B-84E7-87AFE7CD78FCQ36493813-DA754D5C-E71C-4E8F-B417-C141C5794A34Q36644898-D23CA7B2-9F87-4160-A1A4-8100620A7BF2Q37346179-3597CC93-02EC-41F2-9E6B-AAD1E88F92CDQ38212255-837856AE-3EAA-41BA-8B6B-E2EA5DAE06F5Q38749871-D35C36FA-D25C-425A-95B0-E7CB864F2856Q38796220-D8086B27-085B-4C8C-9E14-F5EFE82CDCB3Q38995896-B6E5412D-674E-499D-8E13-AFB3556D3C86Q39428080-0F4A16B7-68F5-4A9F-B1D1-5F9476C29BF9Q40081509-74AFE6F1-C3BF-41FA-B34A-1386C2B8105BQ40284855-A2BF0065-F124-45A8-8CC6-DCE84C1EF723Q42077674-83468EF5-1616-42E8-A7FC-BA29C21E6833Q42170507-2A66BC98-1D3C-4567-8EDF-FFE1703E6FACQ42338756-80204AB0-61B8-4D89-820C-8A53BC7710F8Q42373511-B96BCC9E-2E8C-40A8-A46B-B67B93BC713AQ47835910-627F845F-4C5D-4DC1-83E3-89B83C9F6137Q48155845-D223E63A-1559-4FE5-8891-A5D819A1AC71Q48209437-4890CAFA-BE3D-4415-A857-1A34E79A5A43Q48312549-3A12018A-CC57-45BB-AEB9-C01D27677E33Q52714457-B0DD9A0F-DAB4-4E22-997A-7592C833ECA8Q52721191-B50F0B02-481D-4EE0-ADB8-D308B6484608Q54034630-0DD23FD6-60B5-449F-8BDD-8DCBAED055DFQ58734384-BE6F0BF3-9AE7-4955-94C9-85832FBD88B3Q58792154-8BB2A0B8-81AD-4B51-9679-6FA9CAE13A84Q64064823-2C4FBA80-7B37-4038-8567-6CC5443707E4Q64090981-AB740651-0017-4817-81E2-838092002FBCQ64251160-9884C3C2-0C34-4A15-88F1-DFC3FF115767Q80643517-CFCE2F2F-3FD7-452F-8B93-A998A7553712Q90160827-8F053B68-00AE-4228-BF3C-43D3F322ABD4
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gregory K Friedman
@ast
Gregory K Friedman
@en
Gregory K Friedman
@es
Gregory K Friedman
@nl
Gregory K Friedman
@sl
type
label
Gregory K Friedman
@ast
Gregory K Friedman
@en
Gregory K Friedman
@es
Gregory K Friedman
@nl
Gregory K Friedman
@sl
prefLabel
Gregory K Friedman
@ast
Gregory K Friedman
@en
Gregory K Friedman
@es
Gregory K Friedman
@nl
Gregory K Friedman
@sl
P106
P21
P31
P496
0000-0002-6653-7420